Articles Referencing TRGT
AstraZeneca/TRGT Restructure Deal - Analyst Blog
3/6/2013, 6:15 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) and partner
Targacept, Inc. ( TRGT ) recently
amended their existing agreement. As per the revised agreement,
Targacept has the full rights to develop and... Read >>
Revenues Rise at Incyte - Analyst Blog
2/15/2013, 10:00 am from Zacks.com in Investing, Business, Stocks
Incyte Corporation ( INCY ) reported
earnings of 14 cents per share in the fourth quarter of 2012 as
opposed to a loss of 44 cents per share suffered in the year-ago
quarter. The Zacks... Read >>
Data on Peregrine's Bavituximab - Analyst Blog
2/14/2013, 4:00 pm from Zacks.com in Investing, Business, Stocks
Peregrine Pharmaceuticals ( PPHM ) recently
announced phase II data on its oncology candidate, bavituximab. The
open-label, randomized phase II study was conducted in patients
suffering... Read >>
Amgen Provides Long-Term Update - Analyst Blog
2/13/2013, 4:46 pm from Zacks.com in Investing, Business, Stocks
Amgen ( AMGN ) recently
provided an update on its long-term strategy. The company said that
it intends to focus on the discovery and development of molecules
that address significant unmet... Read >>
SGEN Narrows Loss, Sales Rise - Analyst Blog
2/13/2013, 9:58 am from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) reported fourth
quarter 2012 net loss per share of 9 cents, narrower than the Zacks
Consensus Estimate of a loss of 13 cents and the year-ago loss of
24... Read >>
Theravance Narrows Y/Y Loss - Analyst Blog
2/13/2013, 9:41 am from Zacks.com in Investing, Business, Stocks
Theravance Inc. 's ( THRX ) fourth quarter
2012 loss of 33 cents per share was narrower than the Zacks
Consensus loss estimate of 43 cents and the year-ago loss of 45
cents. The narrower... Read >>
UCB, Amgen Discontinue Study - Analyst Blog
2/12/2013, 4:45 pm from Zacks.com in Investing, Business, Stocks
UCB ( UCBJF ) and
Amgen Inc. ( AMGN ) recently
announced their decision to discontinue a phase III program being
conducted with CDP7851/AMG785 (romosozumab) for the acceleration... Read >>
Priority FDA Review for Celgene Drug - Analyst Blog
2/12/2013, 4:40 pm from Zacks.com in Investing, Business, Stocks
Recently, Celgene Corporation ( CELG ) announced that
the US Food and Drug Administration (FDA) will review the
supplemental New Drug Application (sNDA) for cancer drug... Read >>
Loss at MannKind Wider than Expected - Analyst Blog
2/12/2013, 11:45 am from Zacks.com in Investing, Business, Stocks
MannKind Corporation 's ( MNKD ) loss of 23
cents per share in the fourth quarter of 2012 was wider than the
Zacks Consensus Estimate of a loss of 18 cents. Loss during the
quarter was,... Read >>
Gilead Closes YM Biosciences Buyout - Analyst Blog
2/11/2013, 6:13 pm from Zacks.com in Investing, Business, Stocks
Recently, Gilead Sciences, Inc. ( GILD ) completed its
acquisition of Canada-based drug development company, YM
BioSciences Inc. for $2.95 per share. Through this acquisition,
Gilead aims... Read >>
Lannett Beats, Ups Guidance - Analyst Blog
2/11/2013, 2:24 pm from Zacks.com in Investing, Business, Stocks
Lannett Company, Inc. ( LCI ) reported second
quarter fiscal 2013 earnings of 10 cents per share, above the Zacks
Consensus Estimate of a loss of 3 cents and the year-ago earnings
of 2... Read >>
US Approval for Celgene's Pomalyst - Analyst Blog
2/11/2013, 2:10 pm from Zacks.com in Investing, Business, Stocks
The US Food and Drug Administration (FDA) recently delivered
encouraging news to Celgene Corporation ( CELG ) by approving
the company's oncology drug, Pomalyst.
Pomalyst was approved in... Read >>
Loss Widens at Alnylam, Sales Fall - Analyst Blog
2/8/2013, 12:00 pm from Zacks.com in Investing, Business, Stocks
Alnylam Pharmaceuticals Inc. 's ( ALNY ) fourth quarter
2012 loss of $1.20 per share was narrower than the Zacks Consensus
Estimate of a loss of $1.70. The loss was however wider than... Read >>
Medivation's Xtandi Impresses - Analyst Blog
2/7/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks
Medivation, Inc. ( MDVN ) recently
announced that its partner Astellas Pharma Inc. (
ALPMY ) reported
Xtandi (enzalutamide) sales of about $57 million in the US for the
quarter ended... Read >>
Vivus Unveils Qsymia Study Results - Analyst Blog
2/7/2013, 1:40 pm from Zacks.com in Investing, Business, Stocks
Vivus Inc. ( VVUS ) recently
announced the publication of results from a study regarding its
weight-loss drug, Qsymia. Results from the study revealed that the
weight loss arising from... Read >>